Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder (RestDep)
Primary Purpose
Cognitive Remediation, Cognitive Impairment, Major Depression in Remission
Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
RestDep: Internet-delivered intervention targeting residual cognitive symptoms
Sponsored by
About this trial
This is an interventional treatment trial for Cognitive Remediation
Eligibility Criteria
Inclusion Criteria:
- Previously received treatment for major depressive disorder in primary or secondary healthcare services
- Reporting a history of major depressive disorder symptoms assess using the MINI. few or minor depression symptomss (< 12 MADRS)
- Not meeting criteria for major depressive disorder measured by the MINI)
- Self-reporting residual cognitive symptoms that affects daily functioning (assessed by clinical psychologist)
- No changes in anti-depressant medication under the study period
- Age between 18 and 65 years
- Read and write Norwegian
- Internet and telephone access.
Exclusion Criteria:
- Self-reported substance abuse
- Neurological conditions or damage (e.g. autism, cerebral haemorrhage, and brain tumour)
- Bipolar disorder
- Psychosis.
Sites / Locations
- Haukeland University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Experimental: Intervention
Control: Waitlist
Arm Description
Participants will after baseline receive a guided intervention with weekly therapist support.
Participants will not receive intervention until 7 weeks after baseline.
Outcomes
Primary Outcome Measures
Behaviour Rating Inventory Of Executive Function-Adult
The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A; Roth, Isquith, & Gioia, 2005) is a 75-item self-report questionnaire designed to measure adults' behaviors associated with executive problems.
Perceived Deficit Questionnaire 5
Brief assessment of subjective cognitive difficulties and covers problems with concentration (e.g. "trouble concentrating on things like watching a television program or reading a book?"), memory (e.g. "forget what you talked about after a telephone conversation?"), and executive functioning (e.g. "have trouble getting things organized?"). Every item is rated on a scale of 0 (Never) to 4 (Almost always) to yield a sum score of 0 to 20, with higher scores indicating greater severity of cognitive symptoms.
Secondary Outcome Measures
Rumination Response Scale
The Rumination Response Scale (RRS; Treynor, Gonzalez, & Nolen-Hoeksema, 2003) is a questionnaire frequently used to assess rumination in depression. The 22-item RRS measures the current degree of ruminative responses to depressed mood.
Montgomery Aasberg Depression Rating Scale
The Montgomery Åsberg Depression Rating Scale Self-report (MADRS-S; Svanborg & Åsberg, 2001) is a self-report questionnaire measuring depressive symptoms during the past three days. The MADRS-S consists of 9 items where the following symptoms are rated on a seven-point scale ranging from 0 to 6.
Patient Health Questionaire 9 and 2
The Patient Health Questionnaire-9 (PHQ-9: Kroenke et al., 2001) is a self-report tool used to assess the presence and severity of depressive symptoms. Reliability and validity of the tool have indicated it has sound psychometric properties. Internal consistency of the PHQ-9 has been shown to be high.
The Satisfaction With Life Scale
The SWLS (Kobau et al., 2010) is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life. The scale usually requires only about one minute of a respondent's time.
The Credibility/Expectancy Questionnaire
The Credibility/Expectancy Questionnaire (Borkovec & Nau, 1972) measures treatment credibility and expectancy. Participants rated perceived treatment credibility and expectancy on a scale from 0 to 10 were higher scores indicated better treatment credibility or expectancy.
Log-ins
Number of sessions were participants have logged into the intervention during the intervention period.
Session length
Average length of each log-in during the intervention period.
Days in treatment
Number of days in intervention from receiving intervention until completion.
Full Information
NCT ID
NCT04864353
First Posted
April 21, 2021
Last Updated
April 26, 2021
Sponsor
Haukeland University Hospital
Collaborators
University of Bergen
1. Study Identification
Unique Protocol Identification Number
NCT04864353
Brief Title
Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder
Acronym
RestDep
Official Title
A Guided Internet-delivered Intervention for Adults With Residual Cognitive Symptoms After Major Depressive Disorder: Study Protocol for a Randomized Controlled Trial Investigating Clinical Effects
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2021 (Actual)
Primary Completion Date
December 22, 2023 (Anticipated)
Study Completion Date
January 15, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Haukeland University Hospital
Collaborators
University of Bergen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Background: Cognitive impairment and difficulties are frequently observed in individuals suffering from major depressive disorder. These impairments and difficulties can persist into remission as residual cognitive symptoms. Consequently affecting daily life functioning and quality of life for those affected. Few scalable interventions have targeted these symptoms and measured long-term clinical effects such as depression relapse.
Detailed Description
Background:Cognitive impairment and difficulties are frequently observed in individuals suffering from major depressive disorder. These impairments and difficulties can persist into remission as residual cognitive symptoms. Consequently affecting daily life functioning and quality of life for those affected. Few scalable interventions have targeted these symptoms and measured long-term clinical effects such as depression relapse.
Objectives: The aim is to assess the clinical effects of an intervention targeting residual cognitive symptoms after major depressive disorder. More specifically, if residual cognitive symptoms would be significantly decreased from pre- to post-treatment and remain stable at the 6-month and 2 year follow-up.
Methods: the study is a randomized, waitlist controlled trial including a total of 60 participants (30 in each arm). Primary measures are residual cognitive symptoms measured by the Behavioral Rating Inventory of Executive Functions Adults (BRIEF-A) and Perceived Deficit Questionnaire 5 (PDQ-5). Secondary outcome measures are Depression measured by Montgomery Aasberg Depression Rating Scale and Patient Health Questionnaire 9 and 2 (PHQ-9 and PHQ2), Satisfaction with life measured by Satisfaction with life scale (SWLS), Credibility measured by the Treatment Credibility and Expectation Scale, Rumination measured by the Rumination Response Scale (RRS), Depression screening assessed using the MINI International Psychiatric Interview, Usage data measured by number of log-ins, session length and days in treatment. Quantitative statistical methods will be used to analyze data.
Discussion: The results from the study will contribute to field of internet interventions and provide former depressed adults with an easy access intervention in the treatment of residual cognitive symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Remediation, Cognitive Impairment, Major Depression in Remission
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
Participant
Masking Description
The assessor do not allocate the participant to the intervention or waitlist group.
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental: Intervention
Arm Type
Experimental
Arm Description
Participants will after baseline receive a guided intervention with weekly therapist support.
Arm Title
Control: Waitlist
Arm Type
No Intervention
Arm Description
Participants will not receive intervention until 7 weeks after baseline.
Intervention Type
Behavioral
Intervention Name(s)
RestDep: Internet-delivered intervention targeting residual cognitive symptoms
Intervention Description
The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
Primary Outcome Measure Information:
Title
Behaviour Rating Inventory Of Executive Function-Adult
Description
The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A; Roth, Isquith, & Gioia, 2005) is a 75-item self-report questionnaire designed to measure adults' behaviors associated with executive problems.
Time Frame
2.5 years
Title
Perceived Deficit Questionnaire 5
Description
Brief assessment of subjective cognitive difficulties and covers problems with concentration (e.g. "trouble concentrating on things like watching a television program or reading a book?"), memory (e.g. "forget what you talked about after a telephone conversation?"), and executive functioning (e.g. "have trouble getting things organized?"). Every item is rated on a scale of 0 (Never) to 4 (Almost always) to yield a sum score of 0 to 20, with higher scores indicating greater severity of cognitive symptoms.
Time Frame
2.5 years
Secondary Outcome Measure Information:
Title
Rumination Response Scale
Description
The Rumination Response Scale (RRS; Treynor, Gonzalez, & Nolen-Hoeksema, 2003) is a questionnaire frequently used to assess rumination in depression. The 22-item RRS measures the current degree of ruminative responses to depressed mood.
Time Frame
2.5 years
Title
Montgomery Aasberg Depression Rating Scale
Description
The Montgomery Åsberg Depression Rating Scale Self-report (MADRS-S; Svanborg & Åsberg, 2001) is a self-report questionnaire measuring depressive symptoms during the past three days. The MADRS-S consists of 9 items where the following symptoms are rated on a seven-point scale ranging from 0 to 6.
Time Frame
2.5 years
Title
Patient Health Questionaire 9 and 2
Description
The Patient Health Questionnaire-9 (PHQ-9: Kroenke et al., 2001) is a self-report tool used to assess the presence and severity of depressive symptoms. Reliability and validity of the tool have indicated it has sound psychometric properties. Internal consistency of the PHQ-9 has been shown to be high.
Time Frame
2.5 years
Title
The Satisfaction With Life Scale
Description
The SWLS (Kobau et al., 2010) is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life. The scale usually requires only about one minute of a respondent's time.
Time Frame
2.5 years
Title
The Credibility/Expectancy Questionnaire
Description
The Credibility/Expectancy Questionnaire (Borkovec & Nau, 1972) measures treatment credibility and expectancy. Participants rated perceived treatment credibility and expectancy on a scale from 0 to 10 were higher scores indicated better treatment credibility or expectancy.
Time Frame
8 months
Title
Log-ins
Description
Number of sessions were participants have logged into the intervention during the intervention period.
Time Frame
8 months
Title
Session length
Description
Average length of each log-in during the intervention period.
Time Frame
8 months.
Title
Days in treatment
Description
Number of days in intervention from receiving intervention until completion.
Time Frame
8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Previously received treatment for major depressive disorder in primary or secondary healthcare services
Reporting a history of major depressive disorder symptoms assess using the MINI. few or minor depression symptomss (< 12 MADRS)
Not meeting criteria for major depressive disorder measured by the MINI)
Self-reporting residual cognitive symptoms that affects daily functioning (assessed by clinical psychologist)
No changes in anti-depressant medication under the study period
Age between 18 and 65 years
Read and write Norwegian
Internet and telephone access.
Exclusion Criteria:
Self-reported substance abuse
Neurological conditions or damage (e.g. autism, cerebral haemorrhage, and brain tumour)
Bipolar disorder
Psychosis.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tine Nordgreen, PhD
Phone
+47900 94 913
Email
tine.nordgreen@helse-bergen.no
First Name & Middle Initial & Last Name or Official Title & Degree
Sunniva Myklebost, Msc
Phone
+4798437717
Email
sunniva.myklebost@uib.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tine Nordgreen, PhD
Organizational Affiliation
Projectleader
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haukeland University Hospital
City
Bergen
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tine Nordgreen, PhD
Email
tine.nordgreen@helse-bergen.no
First Name & Middle Initial & Last Name & Degree
Sunniva Myklebost, Msc
Email
sunniva.myklebost@uib.no
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder
We'll reach out to this number within 24 hrs